

Synthesis of New Trisubstituted 4-Aminopiperidines as PAF-Receptor Antagonists

Houcine Benmehdi,^[a,b] Aazdine Lamouri,^[a] Nawal Serradji,^[a] Frédérique Pallois,^[a] and Françoise Heymans^{*[a]}

Keywords: Aminopiperidines / Diastereoisomers / Enamines / Antagonists / Reduction / Biological activity

Two novel classes of 4-aminopiperidines substituted in the 3-position by groups bearing either a carbamate or a ureido function have been synthesized from ethyl 4-oxo-3-piperidinecarboxylate and 3,3'-iminobis(propanenitrile), respectively. The key step in this synthesis, the reduction of the piperidinic β -enamino ester or nitrile, occurred readily. In contrast to published works, the free primary amines could be isolated from the corresponding β -amino ester or nitrile.

Regioselective amidification of the amino group offered two pairs of diastereoisomers which were successfully separated and identified. Measurement of PAF-receptor antagonist activity gave interesting results with an IC_{50} close to the micromolar.

(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2008)

Introduction

After characterization^[1–3] of the platelet activating factor (PAF), elucidation of its structure by three independent research groups^[4–6] and its stereospecific synthesis,^[7–11] sufficient material was available to allow evaluation of the pharmacology and physiopathology of this agent. PAF is recognized as a potent phospholipidic inflammatory mediator and plays a physiopathological role in a variety of clinical conditions such as asthma^[12] and pulmonary dysfunction, acute inflammation, cardiac anaphylaxis, thrombosis, gastrointestinal ulceration, endotoxic shock, allergic skin diseases, transplanted organ rejection, ovariectomy in pregnancy and retinal and corneal diseases.^[13–20] Moreover, in the central nervous system, high PAF concentrations are reported in the cerebrospinal fluid of patients suffering from dementia and an altered immune system.^[21] Since direct infection of neurons by HIV is unlikely and because TNF- α and PAF are both neurotoxic, there is a consensus that neuronal dysfunction and apoptosis are mediated by these soluble factors released by macrophages and microglia in the CNS.^[22] PAF is probably the key element in this phenomenon since TNF- α mediated neuronal apoptosis


can also be blocked by co-incubation with PAF acetylhydrolase,^[21] the main catabolic enzyme for PAF, or by a PAF-receptor antagonist.^[21] Blocking pathologic effects of PAF may therefore be favourable in the treatment of HIV-associated dementia and inflammatory syndrome.^[23]

The search for molecules able to antagonize the effects of PAF has been a part of our work for a while. A study of natural and synthetic inhibitors through their 3D electrostatic potential maps, which take into account volume, conformation and electronic distribution, led us to propose first a simple model for a PAF-receptor comprising a bipolarized cylinder^[24,25] and then a tetrapolarized one.^[26] From these findings we chose piperazine as a support for functionalized moieties, in accordance with the hypotheses, and designed and synthesized potent antagonists.^[27,28] Besides this activity, some of these compounds showed inhibition of HIV-1 replication in monocyte-derived macrophages (MDMs).^[29–31] Following our interest in this field, we undertook to replace the piperazine ring of compounds **1** and **2** (Figure 1), previously synthesized, by an aminopiperidine moiety to evaluate the influence of this ring on both biological activities. These modifications aimed to reinforce the dual anti-PAF and anti-HIV-1 activity of **1** and to increase the anti-PAF potency of **2** (Table 1). Indeed, the aminopiperidine moiety is beneficial in compounds showing various biological activities such as narcotic analgesics,^[32] neurokinin-1 receptor ligands,^[33] 5-HT_{2A} serotonin receptor antagonists,^[34] CCR5 chemokine receptor ligands,^[35] human β_3 -adrenergic receptor antagonists,^[36] potent cognition enhancing drugs,^[37] ORL 1 antagonists^[38] and human-cloned dopamine D₄ receptor antagonists^[39] and has been used as a supporting structure for nitrogen-type antago-

[a] Unité de Pharmacochimie Moléculaire et Systèmes Membranaires (EA 2381), Université Paris 7 – Denis Diderot, case 7066, 2 Place Jussieu, 75251 Paris Cedex 05, France
Fax: +33-144275641
E-mail: heymanf@ccr.jussieu.fr

[b] Laboratoire de Chimie Organique, Substances Naturelles et Analyse (COSNA), Faculté des Sciences, Université Aboubakr Belkaid, B. P. 119, Tlemcen, Algeria

nists.^[40] By using substituted 4-aminopiperidines instead of their piperazine analogues, three important parameters are modified: (i) the flexibility, (ii) the distance between the two nitrogen atoms and, therefore, (iii) the substituent-induced electronic distribution. To the best of our knowledge, the properties of trisubstituted aminopiperidines have been poorly investigated so far; only a few papers have dealt with this topic.^[41–49] This prompted us to develop a new and convenient synthesis of trisubstituted aminopiperidine derivatives and to study their biological activity. We have succeeded in synthesizing new 4-aminopiperidine derivatives substituted in position 3 by groups bearing a carbamate (see Scheme 3) or a ureido (see Scheme 4) function. In these two classes of compounds, we reduced conjugated double bonds by using $\text{NaBH}_3\text{CN}/\text{HCl}$ or CH_3COOH as the reducing agent. The interesting point was that we were able to separate diastereoisomers in a later step.



- 1: $\text{Z} = \text{CH}_2\text{OCONEt}_2$: anti-PAF $\text{IC}_{50} = 8 \mu\text{M}$, anti-HIV $\text{IC}_{50} = 11 \mu\text{M}$.
 2: $\text{Z} = \text{CH}_2\text{NHCONHC}_6\text{H}_{13}$: anti-PAF $\text{IC}_{50} > 100 \mu\text{M}$, anti-HIV $\text{IC}_{50} = 1 \mu\text{M}$.

Figure 1. Piperazine derivatives **1** and **2** and their biological data.

Table 1. In vitro anti-PAF activity of 4-aminopiperidine derivatives.


Compound	Ar ¹	Ar ²	Z	Anti-PAF IC_{50} [μM]
1	TMB	TMB	$-\text{CH}_2\text{OCON}(\text{Et})_2$	8
2	TMB	TMB	$-\text{CH}_2\text{NHCONHC}_6\text{H}_{12}$	>100
<i>trans</i> - 10	PhCH_2	TMB	$-\text{CH}_2\text{OCON}(\text{Et})_2$	0.28
<i>cis</i> - 10	PhCH_2	TMB	$-\text{CH}_2\text{OCON}(\text{Et})_2$	2.63
<i>cis</i> - 12	TMB	TMB	$-\text{CH}_2\text{OCON}(\text{Et})_2$	2.28
<i>cis</i> - 14	PhCH_2	TMB	$-\text{CH}_2\text{NHCONHC}_5\text{H}_{11}$	0.63

Results and Discussion

Chemistry


Carbamate Series

As described in Scheme 1, ethyl 1-benzyl-4-oxo-3-piperidinecarboxylate was treated with a large excess of ammonium acetate in MeOH at room temperature to give the corresponding enamine **3**.^[38]



Scheme 1. Reagents and conditions: (i) AcONH_4 , MeOH, room temp., 1 h, 99%; (ii) NaNH_2 , THF, reflux, 2 h, 81%.


Several attempts were made to perform the *N*-alkylation or *N*-acylation of this enamine **3** by using either benzyl chloride or 3,4,5-trimethoxybenzoyl chloride (TMB-Cl) in refluxing toluene (2 weeks) but none was satisfactory as only traces of the final products were obtained. Three hypotheses could explain these results: (i) a strong conjugated system between the amine function, the double bond and the carbonyl of the ester group, (ii) the formation of a six-membered ring stabilized by hydrogen bonding between the amine and ester functions and finally (iii) an equilibrium displaced more towards the imine than the enamine group under basic conditions. The high stability of the enamine **3** did not allow its reduction into the desired amine under common conditions: NaBH_3CN in MeOH, NaBH_4 in EtOH or NaBH_3CN in *n*BuOH. Published work has revealed that β -enamino esters can easily be reduced into the corresponding β -amino esters.^[50–53] A few methods for the reduction of piperidinic β -enamino esters have been described,^[38,47–49] but the free primary amines could not be isolated from the corresponding piperidinic β -amino esters or nitriles in any of the cases. As shown in Scheme 2, the intermediate **3** was successfully reduced to the key compound **4** after treatment with NaBH_3CN in acidic conditions (HCl or acetic acid) and EtOH at 50 °C, affording in good yield a crude mixture of inseparable diastereoisomers. However, the addition of 3,4,5-trimethoxybenzoyl chloride led to the desired amides **7** as two pairs of diastereoisomers which could be easily separated by silica gel column chromatography. In accord with the results of Kawamoto et al., we chose to use the stereodescriptor *trans* to characterize the stereoisomers presenting the higher R_f on TLC




Scheme 2. Reagents and conditions: **3,4,7**: $\text{Z} = \text{CO}_2\text{Et}$, **5,6,8**: $\text{Z} = \text{CN}$. (i) for **4**: NaBH_3CN , EtOH, HCl, 50 °C, 3 h, 65%; for **6**: NaBH_3CN , EtOH, HCl, 50 °C, 12 h, 81%; (ii) for *cis*- and *trans*-**7**: TMB-Cl, NEt_3 , CH_2Cl_2 , room temp., 4 h, 56.3 and 30.4%, respectively; for *cis*- and *trans*-**8**: TMB-Cl, NEt_3 , THF, room temp., 1 h, 50 and 36%, respectively.

and *cis*, the ones with the smaller R_f (Scheme 2).^[38] The ^1H NMR spectra revealed that each diastereoisomer exists as a pair of enantiomers.

The reduction of *cis*- and *trans*-**7** with $\text{NaBH}_4/\text{LiCl}$ according to the published procedure provided alcohols *cis*- and *trans*-**9** (Scheme 3), respectively.^[54] Treatment of alcohols **9** with first NaH and then by diethylcarbamoyl chloride afforded carbamates *cis*- and *trans*-**10** respectively, in quantitative yields.^[55] Subsequent removal of the *N*-benzyl protecting group using ammonium formate and the Pd/C catalyst generated the derivatives *cis*- and *trans*-**11**.^[56] Our synthesis was completed by a final treatment with 3,4,5-trimethoxybenzoyl chloride to provide compounds *cis*- and *trans*-**12** in 88 and 71% yields, respectively.



Scheme 3. Reagents and conditions: (i) NaBH_4 , LiCl , THF, EtOH, room temp., 36 h, 57 and 83%, respectively; (ii) NaH , THF, $\text{ClCON}(\text{Et})_2$, reflux, 90 min, 81 and 93%, respectively; (iii) Pd/C , HCO_2NH_4 , MeOH, reflux, 1 h, 81 and 43%, respectively; (iv) 3,4,5- $(\text{CH}_3\text{O})_3\text{C}_6\text{H}_2\text{COCl}$, NEt_3 , THF, room temp., 90 min, 88 and 71%, respectively.



Scheme 4. Reagents and conditions: (i) H_2 , Ni , EtOH, concd. HCl (cat.), 60 °C, 12 h, 75 and 37%, respectively; (ii) $\text{C}_5\text{H}_{11}\text{N}=\text{C}=\text{O}$, CH_2Cl_2 , room temp., 2 h, 65%; (iii) Pd/C , HCO_2NH_4 , MeOH, reflux, 1 h, 79 and 60%, respectively; (iv) 3,4,5- $(\text{CH}_3\text{O})_3\text{C}_6\text{H}_2\text{COCl}$, NEt_3 , THF, room temp., overnight, 61 and 74%, respectively.

Ureido Series

As outlined in Scheme 1, compound **5** was obtained in good yield from 3,3'-[(phenylmethyl)imino]bis(propanenitrile)^[57,58] after Thorpe intramolecular cyclization using sodium amide in refluxing THF.^[59] As for the corresponding ester **3**, several strategies to prepare *N*-acylated or *N*-alkylated compounds were investigated but all failed, probably for the reasons we evoked in the ester **3** case. Compound **5** was then reduced by using NaBH_3CN in the presence of concentrated HCl in EtOH to give the corresponding β -aminonitrile **6** as a mixture of inseparable diastereoisomers (Scheme 2). Treatment of its amine function with TMB-Cl gave two pairs of diastereoisomers *cis*- and *trans*-**8** which were separated by silica gel column chromatography in 50 and 36% yields, respectively.

In the next step (Scheme 4) the hydrogenation of the nitrile function of compounds **8** was carried out in acidic ethanol in the presence of the Raney nickel catalyst^[60] and provided the corresponding amines *cis*- and *trans*-**13** which reacted with pentyl isocyanate to give the ureido compounds *cis*- and *trans*-**14** in moderate yields. Debenzylation occurred with HCO_2NH_4 and Pd/C in refluxing methanol and gave *cis*- and *trans*-**15** in 79 and 60% yields, respectively. These compounds were then acylated with TMB-Cl to the desired final products *cis*- and *trans*-**16** in 61 and 74% yields, respectively.

Biological Results

The inhibition of platelet aggregation was evaluated by the method of Cazenave et al. by using platelet-rich plasma (PRP) of New Zealand rabbits.^[61] The intermediates were tested for their ability to antagonize PAF-induced platelet aggregation. All the results obtained are listed in Table 1. In the case of the carbamate series, *cis*-**12** and the reference compound **1** present similar anti-PAF activities showing that the piperazine ring of **1** can be replaced by an aminopiperidine moiety (*cis*-**12**) without any alteration of the biological activity. Replacement of one of the 3,4,5-trimethoxybenzoyl groups of **1** by a benzyl substituent (*trans*- and

cis-**10**) leads to potent compounds and diastereoisomers: *trans*-**10** (IC_{50} = 0.28 μ M) is nearly 10 times more active than its analogue *cis*-**10** (IC_{50} = 2.63 μ M). In the ureido series, *cis*-**14** presents a good antagonism (IC_{50} = 0.63 μ M) towards the PAF-receptor in contrast to the piperazine analogue **2** which is inactive. Evaluation of the HIV-1 activity of our synthesized trisubstituted 4-aminopiperidine derivatives is currently underway.

Conclusions

In summary, an efficient synthesis of trisubstituted aminopiperidine with ureido and carbamate functions has been developed. Contrary to the previously published papers, we succeeded in isolating the β -amino ester **4** and β -aminonitrile **6** which are the key intermediates in the preparation of other compounds. Two pairs of diastereoisomers in each series were isolated and characterized by 1H NMR spectroscopy. Preliminary biological results are interesting as all the compounds present anti-PAF activity in the micromolar range. Anti-retroviral evaluation of the racemic mixtures of *cis*-/*trans*-**12** and *cis*-/*trans*-**16** is currently under investigation and chiral resolution of these mixtures could be attempted if interesting results are obtained in order to test the two enantiomeric forms separately.

Experimental Section

Materials and Methods: All reactions were monitored by thin-layer chromatography on TLC plastic sheets (silica gel 60F254, layer thickness 0.2 mm) from Merck. Column chromatography purification was carried out on silica gel 60 (particle size 0.063–0.200 mm) from Merck without any special treatment. All melting points were determined with a digital melting point apparatus (Electrothermal) and are uncorrected. The structures of all compounds were confirmed by IR, 1H and ^{13}C NMR spectra. IR spectra were recorded with an ATI Mattson Genesis Series FTIR infrared spectrometer (4000–600 cm^{-1}). 1H and ^{13}C NMR spectra were recorded in $CDCl_3$ with a Bruker AC 200 spectrometer. Chemical shifts (δ) were measured in ppm and are reported relative to the solvent peak of TMS. All elemental analyses were within $\pm 0.4\%$ of theoretical values.

Ethyl 4-Amino-1-benzyl-1,2,5,6-tetrahydro-3-pyridinecarboxylate (3): AcONH₄ (51 g, 662 mmol) was added to a solution of 1-benzyl-3-ethoxycarbonyl-4-piperidone (20 g, 67 mmol) in methanol (400 mL) at room temperature and the reaction mixture was stirred for 1 h and concentrated in vacuo. The residue was dissolved in CH_2Cl_2 and washed successively with a solution of NaHCO₃ and water. The organic layer was dried with MgSO₄, filtered and concentrated to dryness to give compound **3** as a colourless oil (16 g, yield 99%). R_f = 0.25 (CH_2Cl_2 /MeOH, 95:5 v/v). IR (film): $\tilde{\nu}$ = 3440–3331 (NH₂), 2903–2803 (CH₂ and CH₃), 1671 (CO₂Et), 1621 (C=C), 1548 (ArC=C) cm^{-1} . 1H NMR ($CDCl_3$): δ = 7.21–7.37 (m, 5 H, ArH), 6.00 (br. s, 2 H, NH₂), 4.07–4.17 (q, J = 7 Hz, 2 H, OCH₂CH₃), 3.61 (s, 2 H, ArCH₂), 3.24 (s, 2 H, N-CH₂ piperidine), 2.47–2.53 (t, J = 5.6 Hz, 2 H, N-CH₂ piperidine), 2.26–2.31 (t, J = 5.6 Hz, 2 H, N-CH₂CH₂), 1.20–1.27 (t, J = 7 Hz, 3 H, OCH₂CH₃) ppm.

4-Amino-1-benzyl-3-cyano-1,2,5,6-tetrahydropyridine (5): A suspension of sodium amide (7.25 g, 18 mmol) was added to a solution

of 3,3'-[(phenylmethyl)imino]bis(propanenitrile)^[58,59] (33 g, 0.15 mol) in THF (400 mL). The solution was then stirred and refluxed for 2 h. The sodium amide excess was destroyed with water at 0 °C and the solvents were removed to dryness. The residue was dissolved in CH_2Cl_2 , washed with water and dried with MgSO₄. The organic layer was then concentrated in vacuo. Compound **5** was obtained as a yellow solid (27 g, yield 81%). M.p. 152 °C, R_f = 0.51 (CH_2Cl_2 /MeOH, 90:10, v/v). IR (KBr): $\tilde{\nu}$ = 3427 (NH₂), 2928, 2823 (CH₂), 1642 (C=C), 1615 (ArC=C), 2181 (CN) cm^{-1} . 1H NMR ($CDCl_3$): δ = 7.25–7.32 (m, 5 H, ArH), 4.39 (s, 2 H, NH₂), 3.58 (s, 2 H, ArCH₂), 3.07 (s, 2 H, CH₂ piperidine), 2.58–2.64 (t, J = 5.73 Hz, 2 H, CH₂ piperidine), 2.2–2.3 (t, J = 5.71 Hz, 2 H, CH₂ piperidine) ppm. ^{13}C NMR ($CDCl_3$): δ = 154.7 (C=C-NH₂), 137.5, 128.4, 127.4 (ArC=C), 119.1 (CN), 72.6 (C=C-CN), 61.5, 50.7, 48.2, 28.0 (ArCH₂ and CH₂ piperidine) ppm.

General Procedure for the Synthesis of Compounds 4 and 6: NaBH₃CN (2 equiv.) and acetic acid or hydrochloric acid (3 equiv.) were added to a solution of the enamine **3** or **5** in ethanol at room temperature and the mixture was heated at 50 °C until the reaction was complete (TLC monitoring). After cooling, the excess NaBH₃CN was destroyed with water. After evaporation of the solvents, the residue was dissolved in CH_2Cl_2 and washed with a solution of NaHCO₃ and water. The organic layer was dried with MgSO₄, filtered and concentrated in vacuo.

Ethyl 4-Amino-1-benzyl-3-piperidinecarboxylate (4): Compound **4** was prepared according to the general procedure using **3** (34 g, 130 mmol) in ethanol (500 mL), NaBH₃CN (16.5 g, 262 mmol) and acetic acid (18.5 mL, 323 mmol). Further purification by silica gel column chromatography (CH_2Cl_2 then CH_2Cl_2 /MeOH, 97:3, v/v) gave the title compound as a green oil (18 g, yield 65%). R_f = 0.34 (CH_2Cl_2 /MeOH, 93:7, v/v). IR (film): $\tilde{\nu}$ = 3378 (NH₂), 2925–2808 (CH₂ and CH₃), 1726 (CO₂Et), 1601 (ArC=C) cm^{-1} . 1H NMR ($CDCl_3$): δ = 7.22–7.30 (m, 5 H, ArH), 4.07–4.18 (q, J = 7.2 Hz, 2 H, OCH₂CH₃), 3.06–3.44 (m, 2 H, Ar-CH₂), 2.36–3.08 (2m, 4 H, CH₂ and CH piperidine), 2.28 (s, 2 H, NH₂), 1.41–2.14 (3 m, 4 H, NCH₂CH₂), 1.19–1.26 (t, J = 7 Hz, 3 H, OCH₂CH₃) ppm. ^{13}C NMR ($CDCl_3$): δ = 172.9 (C=O ester), 137.8 (ArC=C), 129.0, 128.7, 128.0, 126.9 (ArCH=CH), 62.2 (OCH₂CH₃), 60.3 (ArCH₂), 53.8, 51.9, 33.4 (CH₂ piperidine), 51.0, 50.2 (CH piperidine), 14.0 (OCH₂CH₃) ppm.

4-Amino-1-benzyl-3-cyanopiperidine (6): Concentrated hydrochloric acid (12 N, 4.5 mL, 140 mmol) was added to a mixture of **5** (10.6 g, 50 mmol) in ethanol (100 mL) and NaBH₃CN (6.25 g, 100 mmol) was added. The solution was heated at 50 °C for 12 h. Purification by silica gel column chromatography eluted with CH_2Cl_2 and CH_2Cl_2 /MeOH (97:3, v/v) gave the title compound as a green oil (8.6 g, yield 80%). R_f = 0.23 (CH_2Cl_2 /MeOH, 97:3, v/v). IR (film): $\tilde{\nu}$ = 3371–3303 (NH₂), 2941–2807 (CH₂), 1599 (ArC=C), 2239 (CN) cm^{-1} . 1H NMR ($CDCl_3$): δ = 7.16–7.27 (m, 5 H, ArH), 3.53 (d, J = 13.4 Hz, ArCH), 3.4 (d, J = 13.4 Hz, ArCH), 2.73–2.87 (m, 4 H, CH and CH₂ piperidine), 2.13–2.06 (m, 2 H, CH₂ piperidine), 1.71–1.64 (q, J = 3.9 Hz, 2 H, CH₂ piperidine) ppm. ^{13}C NMR ($CDCl_3$): δ = 137.4, 137.1 (ArC=C), 128.4, 128.2, 127.9, 126.9, 126.7 (ArCH=CH), 119.7, 119.2 (CN), 61.5, 61.3 (ArCH₂), 53.1, 52.2, 51.3, 33.3, 31.8 (CH₂ piperidine), 50.9, 48.7, 37.9, 37.2 (CH piperidine) ppm.

General Procedure for the Synthesis of Compounds cis-7, trans-7, cis-8, trans-8, cis-12, trans-12, cis-16 and trans-16: A solution of 3,4,5-trimethoxybenzoyl chloride (1.1 equiv.) in dichloromethane or THF was added dropwise to a solution of **4**, **6**, *cis*-**11**, *trans*-**11**, *cis*-**15** or *trans*-**15** in dichloromethane or THF and triethylamine (3 equiv.). The solution was stirred at room temperature until the

reaction was complete (TLC monitoring). After washing with a NaHCO_3 solution and water, the organic layer was dried with MgSO_4 , filtered and concentrated to dryness. The residue was purified by chromatography on a silica gel column as indicated.

Ethyl 1-Benzyl-4-(3,4,5-trimethoxybenzoylamino)-3-piperidinecarboxylate (*trans*- and *cis*-7): Compounds *trans*- and *cis*-7 were prepared by using **4** (11.8 g, 45 mmol) in dichloromethane (150 mL), triethylamine (19 mL, 135 mmol) and a solution of 3,4,5-trimethoxybenzoyl chloride (11.43 g, 49.58 mmol) in dichloromethane (50 mL). The reaction mixture was stirred at room temperature for 4 h and after usual treatment a mixture of the two pairs of diastereoisomers was obtained as a white solid. Separation by silica gel column chromatography using (CH_2Cl_2 then $\text{CH}_2\text{Cl}_2/\text{MeOH}$, 9:1, v/v) as eluent afforded *trans*-7 (6.7 g, 30.4% yield), m.p. 163 °C, R_f = 0.34 ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 97:3, v/v), and *cis*-7 (12.4 g, 56.3% yield), m.p. 146 °C, R_f = 0.26 ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 97:3, v/v), as white solids. IR (KBr) (*trans*-7 diastereoisomer): $\tilde{\nu}$ = 3341 (NH amide), 2903 (CH_2 and CH_3), 1725 (CO_2Et), 1630 (C=O amide), 1581 ($\text{ArC}=\text{C}$) cm^{-1} ; (*cis*-7 diastereoisomer): $\tilde{\nu}$ = 3240 (NH amide), 2929–2802 (CH_2 and CH_3), 1733 (CO_2Et), 1628 (C=O amide), 1582 ($\text{ArC}=\text{C}$) cm^{-1} . ^1H NMR (CDCl_3) (*trans*-7 diastereoisomer): δ = 7.38–7.43 (d, J = 10 Hz, 1 H, NHCO), 7.23–7.28 (m, 5 H, ArH), 6.98 (s, 2 H, ArH), 4.2–4.4 (m, 1 H, CH piperidine), 4.07–4.17 (q, J = 7.14 Hz, 2 H, OCH_2CH_3), 3.85–3.88 [2 s, 9 H, (OCH_3)₃], 3.32–3.62 (dd, J = 13.3 Hz, 2 H, ArCH_2), 2.20–3.32 (m, 7 H, CH and CH_2 piperidine), 1.13–1.20 (t, J = 7.14 Hz, 3 H, OCH_2CH_3); (*cis*-7 diastereoisomer): δ = 7.26–7.32 (m, 5 H, ArH), 6.96 (s, 2 H, ArH), 6.17–6.21 (d, J = 8 Hz, 1 H, NHCO), 4.03–4.10 (q, J = 7 Hz, 2 H, OCH_2CH_3), 4.10–4.14 (m, 1 H, CH piperidine), 3.86–3.88 [2 s, 9 H, (OCH_3)₃], 3.55 (s, 2 H, ArCH_2), 1.5–3.1 (m, 7 H, CH and CH_2 piperidine), 1.12–1.19 (t, J = 7.14 Hz, 3 H, OCH_2CH_3) ppm. ^{13}C NMR (CDCl_3) (*trans*-7 diastereoisomer): δ = 173.5 (C=O ester), 166.0 (C=O amide), 153.0, 140.7, 138.3, 130.0 ($\text{ArC}=\text{C}$), 128.7, 128.0, 126.9, 104.2 ($\text{ArCH}=\text{CH}$), 62.4 (ArCH_2), 60.8, 56.2 (OCH_3), 60.5 (OCH_2CH_3), 54.4, 53.0, 29.0 (CH_2 piperidine), 47.1, 44.3 (CH piperidine), 13.9 (OCH_2CH_3); (*cis*-7 diastereoisomer): δ = 173.5 (C=O ester), 166.0 (C=O amide), 153.1, 140.0, 138.3, 130.0 ($\text{ArC}=\text{C}$), 128.7, 128.0, 126.9, 104.2 ($\text{ArCH}=\text{CH}$), 62.4 (ArCH_2), 56.2, 60.8 (OCH_3), 60.5 (OCH_2CH_3), 54.4, 53.0, 29.0 (CH_2 piperidine), 47.2, 44.3 (CH piperidine), 14.0 (OCH_2CH_3) ppm.

1-Benzyl-3-hydroxymethyl-4-(3,4,5-trimethoxybenzoylamino)piperidine (*trans*-9): Dry LiCl (1.48 g, 34.84 mmol), NaBH_4 (0.66 g, 17.36 mmol) and absolute EtOH (25 mL) were added successively to a solution of *trans*-7 (2 g, 438 mmol) in anhydrous THF (50 mL). The reaction mixture was stirred at room temperature for 36 h under argon. The excess NaBH_4 and LiCl were destroyed with water and the solvents were evaporated to dryness. The residue was dissolved in CH_2Cl_2 and washed with water and brine. The organic layer was dried with MgSO_4 , filtered and concentrated in vacuo. Further purification by silica gel column chromatography (CH_2Cl_2 then $\text{CH}_2\text{Cl}_2/\text{MeOH}$) gave *trans*-9 as a white solid (1.5 g, yield 83%). M.p. 143 °C, R_f = 0.20 ($\text{CH}_2\text{Cl}_2/1\%$ MeOH, 5:5, v/v). IR (KBr): $\tilde{\nu}$ = 3409 (OH), 3308 (NH amide), 2921–2856 (CH_2 and CH_3), 1626 (C=O amide), 1580 ($\text{ArC}=\text{C}$), 1128 (OCH_3) cm^{-1} . ^1H NMR (CDCl_3): δ = 7.27–7.33 (m, 5 H, ArH), 7.01 (s, 2 H, ArH), 6.80–6.85 (br. d, 1 H, NHCO), 4.22–4.42 (m, 1 H, CH piperidine), 3.87–3.91 [2 s, 9 H, (OCH_3)₃], 3.79–3.82 (m, 3 H, CH_2OH), 3.53 (s, 2 H, ArCH_2), 1.98–2.7 (m, 7 H, CH and CH_2 piperidine) ppm. ^{13}C NMR (CDCl_3): δ = 168.0 (C=O amide), 153.1, 141.1, 137.9 ($\text{ArC}=\text{C}$), 129.1, 128.1, 127.0, 104.4 ($\text{ArCH}=\text{CH}$), 62.9 (ArCH_2), 61.7 (CH_2OH), 60.7, 56.2 (OCH_3), 55.6, 52.5, 31.7 (CH_2 piperidine), 48.2, 44.9 (CH piperidine) ppm.

[1-Benzyl-4-(3,4,5-trimethoxybenzoylamino)piperidin-3-yl]methyl *N,N*-Diethylcarbamate (*trans*-10): NaH (0.12 g, 5 mmol) was added to a solution of *trans*-9 (1 g, 2.4 mmol) in dry THF (60 mL). The mixture was stirred at 60 °C for 0.5 h, then a solution of diethylcarbamoyl chloride (0.36 g, 2.65 mmol) was added dropwise. The reaction mixture was stirred at 60 °C for 1 h. The excess NaH was destroyed with water and the solvents were removed under reduced pressure. The crude product was dissolved in CH_2Cl_2 and washed with water. The organic layer was dried with MgSO_4 , filtered and concentrated in vacuo. Purification by silica gel column chromatography, eluting with CH_2Cl_2 and $\text{CH}_2\text{Cl}_2/1\%$ MeOH, gave the title compound as a white solid (1 g, yield 81%). M.p. 133 °C, R_f = 0.43 ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 93:7, v/v). $\text{C}_{28}\text{H}_{39}\text{N}_3\text{O}_6 \cdot \frac{3}{4}\text{H}_2\text{O}$ (526.5): C 63.75, H 7.96, N 7.96; found C 63.91, H 7.65, N 7.95. IR (KBr): $\tilde{\nu}$ = 3307 (NH amide), 2922 (CH_2 and CH_3), 1703 (C=O carbamate), 1626 (C=O amide), 1583 ($\text{ArC}=\text{C}$), 1128 (OCH_3) cm^{-1} . ^1H NMR (CDCl_3): δ = 7.6–7.7 (br. d, 1 H, NHCO), 7.26–7.33 (m, 5 H, ArH), 7.20 (s, 2 H, ArH), 4.2–4.51 (m, 2 H, CH_2OH), 4.0–4.18 (m, 1 H, CH piperidine), 3.87–3.93 [2 s, 9 H, (OCH_3)₃], 3.47–3.6 (dd, J = 10 Hz, 2 H, ArCH_2), 3.0–3.4 [br. q, 4 H, $\text{N}(\text{CH}_2\text{CH}_3)_2$], 1.50–2.83 (m, 7 H, CH and CH_2 piperidine), 0.9–1.2 [br. t, 6 H, $\text{N}(\text{CH}_2\text{CH}_3)_2$] ppm. ^{13}C NMR (CDCl_3): δ = 166.7 (C=O amide), 156.0 (C=O ureido), 152.9, 140.5, 138.1 ($\text{ArC}=\text{C}$), 129.7, 128.8, 128.1, 127.0, 104.3 ($\text{ArCH}=\text{CH}$), 64.9 [$\text{CH}_2\text{OCON}(\text{Et})_2$], 62.7 (ArCH_2), 60.7, 56.1 (OCH_3), 57.0, 52.2, 32.1 (CH_2 piperidine), 49.1, 42.4 (CH piperidine), 41.7, 41.2 (NCH_2CH_3), 13.8, 13.3 (NCH_2CH_3) ppm.

General Procedure for the Synthesis of Compounds *cis*-11, *trans*-11, *cis*-15 and *trans*-15: Ammonium formate, triethylamine (3 equiv.) and palladium on activated carbon were added to a solution of *cis*-10, *trans*-10, *cis*-14 or *trans*-14 in methanol. The mixture was refluxed until the reaction was complete (TLC monitoring). After cooling at room temperature, filtration of Pd/C and evaporation of the solvent to dryness, the residue was dissolved in CH_2Cl_2 and washed with water. The organic layer was dried with MgSO_4 , filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography as indicated.

[4-(3,4,5-Trimethoxybenzoylamino)piperidin-3-yl]methyl *N,N*-Diethylcarbamate (*trans*-11): This compound was prepared using a solution of *trans*-10 (1 g, 1.94 mmol) in methanol (80 mL), ammonium formate (1.5 g, 23.8 mmol) and Pd/C (0.3 g). The reaction mixture was refluxed for 1 h. After concentrating in vacuo, purification on a silica gel column chromatography, eluting with ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 97:3 and 90:10, v/v), gave the title compound as a viscous solid (0.35 g, yield 43%). R_f = 0.38 ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 80:20, v/v). IR (film): $\tilde{\nu}$ = 3346 (NH, piperidine and NH amide), 2924–2855 (CH_2 and CH_3), 1676 (C=O carbamate), 1636 (C=O amide), 1583 ($\text{ArC}=\text{C}$), 1125 (OCH_3) cm^{-1} . ^1H NMR (CDCl_3): δ = 7.6–7.8 (br. d, 1 H, NHCO), 7.1–7.25 (s, 2 H, ArH), 4.35–4.45 (d, J = 6 Hz, 1 H, HN piperidine), 4.15–4.3 (m, 1 H, CH piperidine), 3.75–4.00 [2 s, 9 H, (OCH_3)₃], 3.0–3.4 [br. q, 4 H, $\text{N}(\text{CH}_2\text{CH}_3)_2$], 2.6–3.0 (m, 2 H, CH_2OCO), 1.2–3.0 (m, 7 H, CH and CH_2 piperidine), 1.01–1.08 [t, J = 7 Hz, 6 H, $\text{N}(\text{CH}_2\text{CH}_3)_2$] ppm. ^{13}C NMR (CDCl_3): δ = 166.5 (C=O amide), 155.9 (C=O ureido), 152.9, 140.4, 129.6, 104.3 ($\text{ArC}=\text{C}$), 64.8 [$\text{CH}_2\text{OCON}(\text{Et})_2$], 60.6, 56.0 (OCH_3), 50.0, 45.2, 33.1 (CH_2 piperidine), 49.2, 43.1 (CH piperidine), 41.7, 41.1 (NCH_2CH_3), 13.9, 13.2 [$\text{N}(\text{CH}_2\text{CH}_3)_2$] ppm.

[1-(3,4,5-Trimethoxybenzoyl)-4-(3,4,5-trimethoxybenzoylamino)piperidin-3-yl]methyl *N,N*-Diethylcarbamate (*trans*-12): Compound *trans*-12 was prepared using *trans*-11 (0.34 g, 0.8 mmol), triethylamine (0.3 mL, 2.1 mmol) in THF (60 mL) and a solution of 3,4,5-trimethoxybenzoyl chloride (0.20 g, 0.86 mmol) in THF (10 mL). The reaction mixture was stirred at room temperature for 1.5 h.

Evaporation of THF to dryness and crystallization of the crude product in methanol gave *trans*-**12** as a white solid (0.35 g, yield 71 %). M.p. 240 °C, R_f = 0.33 (CH₂Cl₂/MeOH, 95:5, v/v). C₃₁H₄₃N₃O₁₀ (617): C 60.27, H 7.01, N 6.80; found C 60.36, H 7.04, N 6.75. IR (KBr): $\tilde{\nu}$ = 3368 (NH amide), 2925–2856 (CH₂ and CH₃), 1695 (C=O carbamate), 1656 (C=O amide), 1585 (ArC=C), 1123 (OCH₃) cm⁻¹. ¹H NMR (CDCl₃): δ = 7.22 (s, 2 H, ArH), 6.63 (s, 2 H, ArH), 4.25–4.5 (m, 2 H, NHCO and CH piperidine), 4.1–4.25 (m, 2 H, CH₂OCO), 3.86–3.89 [2 s, 18 H, (OCH₃)₆], 3.0–3.4 [br. q, 4 H, N(CH₂CH₃)₂], 1.5–3.4 (m, 7 H, CH and CH₂ piperidine), 0.9–1.2 [br. t, 6 H, N(CH₂CH₃)₂] ppm. ¹³C NMR (CDCl₃): δ = 170.8 (C=O amide), 166.5 (C=O amide), 153.3 (C=O ureido), 153.0, 130.8, 129.1, 148.4, 148.7, 104.5, 104.2 (ArC=C), 60.8, 56.2, 56.1 (OCH₃ and CH piperidine), 41.9, 41.2, 28.1 (CH₂ piperidine), 13.9, 13.3 [N(CH₂CH₃)] ppm.

1-Benzyl-3-hydroxymethyl-4-(3,4,5-trimethoxybenzoylamino)piperidine (*cis*-9**):** Compound *cis*-**9** was prepared from *cis*-**7** (3.17 g, 6.95 mmol), LiCl (1.18 g, 27.78 mmol) and NaBH₄ (0.53 g, 13.94 mmol) using the procedure described for *trans*-**9** and was obtained as a white solid (1.5 g, yield 57%). M.p. 164 °C, R_f = 0.23 (CH₂Cl₂/MeOH, 93:07, v/v). IR (KBr): $\tilde{\nu}$ = 3422 (OH), 3330 (NH amide), 2941–2836 (CH₂ and CH₃), 1633 (C=O amide), 1582 (ArC=C), 1128 (OCH₃) cm⁻¹. ¹H NMR (CDCl₃): δ = 7.25–7.30 (m, 5 H, ArH), 6.9 (s, 2 H, ArH), 6.20–6.24 (d, J = 8.48 Hz, 1 H, NHCO), 3.90–3.98 (m, 2 H, CH piperidine and OH), 3.87 [2 s, 9 H, (OCH₃)₃], 3.60 (s, 2 H, ArCH₂), 1.5–3.61 (m, 9 H, CH and CH₂ piperidine and CH₂OH) ppm. ¹³C NMR (CDCl₃): δ = 167.0 (C=O amide), 153.1, 137.2, 141.0 (ArC=C), 129.7, 128.9, 128.4, 127.4, 104.4 (ArCH=CH), 63.7 (ArCH₂), 62.9 (CH₂OH), 60.8, 56.3 (OCH₃), 55.3, 51.6, 29.4 (CH₂ piperidine), 47.6, 38.9 (CH piperidine) ppm.

[1-Benzyl-4-(3,4,5-trimethoxybenzoylamino)piperidin-3-yl]methyl *N,N*-Diethylcarbamate (*cis*-10**):** Compound *cis*-**10** was prepared from *cis*-**9** (1.52 g, 3.48 mmol), NaH (0.17 g, 7.4 mmol) and diethylcarbamoyl chloride (0.52 g, 3.83 mmol) using the same procedure as for *trans*-**10** and was obtained as a white solid (1.65 g, yield 93 %). M.p. 186 °C, R_f = 0.33 (CH₂Cl₂/MeOH, 93:07, v/v). C₂₈H₃₉N₃O₆ (513): C 65.47, H 7.65, N 8.18; found C 65.81, H 7.44, N 7.79. IR (KBr): $\tilde{\nu}$ = 3317 (NH amide), 2936–2836 (CH₂ and CH₃), 1696 (C=O carbamate), 1626 (C=O amide), 1583 (ArC=C), 1127 (OCH₃) cm⁻¹. ¹H NMR (CDCl₃): δ = 7.27–7.32 (m, 5 H, ArH), 7.26 (s, 2 H, ArH), 7.00–7.11 (br. d, 1 H, NHCO), 4.40–4.45 (2 dd, 1 H, CH piperidine), 3.86–3.91 [2 s, 9 H, (OCH₃)₃], 3.62–3.66 (m, 2 H, CH₂O), 3.54 (s, 2 H, ArCH₂), 3.00–3.35 [br. q, 4 H, N(CH₂CH₃)₂], 1.5–3.00 (m, 7 H, CH and CH₂ piperidine), 0.90–1.20 [br. t, 6 H, N(CH₂CH₃)₂] ppm. ¹³C NMR (CDCl₃): δ = 166.7 (C=O amide), 155.9 (C=O carbamate), 152.9, 140.4, 138.0 (ArC=C), 129.7, 128.8, 128.1, 126.9, 104.3 (ArCH=CH), 64.9 [CH₂OCON(Et)₂], 62.7 (ArCH₂), 60.7, 56.0 (OCH₃), 57.0, 52.2, 32.1 (CH₂ piperidine), 49.1, 42.3 (CH piperidine), 41.7, 41.1 [N(CH₂CH₃)], 13.8, 13.3 [N(CH₂CH₃)] ppm.

[4-(3,4,5-Trimethoxybenzoylamino)piperidin-3-yl]methyl *N,N*-Diethylcarbamate (*cis*-11**):** Compound *cis*-**11** was prepared from *cis*-**10** (1.35 g, 2.63 mmol), ammonium formate (1.66 g, 26.32 mmol) and Pd/C (0.5 g) using the procedure described for *trans*-**11**. Compound *cis*-**11** was obtained as a white solid (0.90 g, yield 81%). M.p. 149 °C, R_f = 0.21 (CH₂Cl₂/MeOH, 80:20, v/v). IR (KBr): $\tilde{\nu}$ = 3328–3269 (NH of piperidine and NH amide), 2940 (CH₂ and CH₃), 1691 (C=O carbamate), 1625 (C=O amide), 1582 (ArC=C), 1127 (OCH₃) cm⁻¹. ¹H NMR (CDCl₃): δ = 7.12–7.18 (m, 3 H, ArH and NHCO), 4.40–4.45 (2 dd, 1 H, CH piperidine), 3.85–3.91 [2 s, 9 H, (OCH₃)₃], 3.60–3.69 (m, 2 H, CH₂O), 3.17–3.28 [q, J = 7 Hz, 4 H,

N(CH₂CH₃)₂], 1.4–3.28 (m, 7 H, CH and CH₂ piperidine), 2.38 (s, 1 H, HN piperidine), 1.05–1.12 [t, J = 7 Hz, 6 H, N(CH₂CH₃)₂] ppm. ¹³C NMR (CDCl₃): δ = 166.5 (C=O amide), 155.9 (C=O carbamate), 152.9, 140.4, 129.6, 104.4 (ArC=C), 64.8 [CH₂OCON(Et)₂], 60.6, 56.0 (OCH₃), 50.0, 45.2, 33.1 (CH₂ piperidine), 49.2, 43.1 (CH piperidine), 41.7, 41.1 [N(CH₂CH₃)], 13.9, 13.2 [N(CH₂CH₃)] ppm.

[1-(3,4,5-Trimethoxybenzoyl)-4-(3,4,5-trimethoxybenzoylamino)-piperidin-3-yl]methyl *N,N*-Diethylcarbamate (*cis*-12**):** Compound *cis*-**12** was prepared from *cis*-**11** (0.35 g, 86 mmol), triethylamine (0.36 mL, 2.56 mmol) and a solution of 3,4,5-trimethoxybenzoyl chloride (0.25 g, 1 mmol) using the same process as for *trans*-**12**. Compound *cis*-**12** was obtained as a white solid (0.45 g, yield 88 %). M.p. 112 °C, R_f = 0.20 (CH₂Cl₂/MeOH, 95:05, v/v). C₃₁H₄₃N₃O₁₀·H₂O (635): C 57.76, H 7.14, N 6.52; found C 57.86, H 7.28, N 6.20. IR (KBr): $\tilde{\nu}$ = 3345 (NH amide), 3055 (ArCH=CH), 2974–2836 (CH₂ and CH₃), 1695 (C=O carbamate), 1624 (C=O amide), 1585 (ArC=C), 1127 (OCH₃) cm⁻¹. ¹H NMR (CDCl₃): δ = 7.18 (s, 2 H, ArH), 6.61 (s, 2 H, ArH), 4.47–4.54 (br. d, J = 12.2 Hz, 1 H, NHCO), 3.85–3.92 [2 s, 18 H, (OCH₃)₆], 3.5–3.92 (m, 3 H, CH₂O and CH piperidine), 3.0–3.4 [br. q, 4 H, N(CH₂CH₃)₂], 1.0–3.1 (m, 7 H, CH and CH₂ piperidine), 1.0–1.12 [br. t, 6 H, N(CH₂CH₃)₂] ppm. ¹³C NMR (CDCl₃): δ = 170.1 (C=O amide), 166.8 (C=O amide), 153.2 (C=O ureido), 153.0, 140.8, 139.2, 130.8, 129.2, 104.4, 104.0 (ArC=C), 64.2 [CH₂OCON(Et)₂], 60.8, 56.1, 49.3 (OCH₃), 41.9, 41.3, 21.1 (CH₂ piperidine), 13.8, 13.3 N (CH₂CH₃) ppm.

1-Benzyl-3-cyano-4-(3,4,5-trimethoxybenzoylamino)piperidine (*cis*-8** and *trans*-**8**):** Compounds *cis*- and *trans*-**8** were prepared using **6** (13.3 g, 61.86 mmol), triethylamine (21.7 mL, 154.4 mmol) in THF (150 mL) and a solution of 3,4,5-trimethoxybenzoyl chloride (15 g, 65 mmol) in THF (50 mL). The reaction mixture was stirred at room temperature for 1 h. After evaporation of the solvent, the residue was dissolved in CH₂Cl₂ and crystallized by adding methanol to give 19.4 g (yield 78%) of a mixture of *cis*-**8** and *trans*-**8** diastereoisomers as a white powder. They were separated by silica gel column chromatography using CH₂Cl₂ then CH₂Cl₂/MeOH (98:2, v/v) as eluent to give 7 g of *trans*-**8** (yield 36%), m.p. 200 °C, R_f = 0.54 (CH₂Cl₂/MeOH, 95:5, v/v), and 9.7 g of *cis*-**8** (yield 50%), m.p. 195 °C, R_f = 0.29 (CH₂Cl₂/MeOH, 95:5, v/v). IR (KBr) (*trans*-**8** diastereoisomer): $\tilde{\nu}$ = 3308 (NH amide), 3054 (ArC-H), 2943–2810 (CH₂), 2305–2241 (CN), 1632 (C=O amide), 1582 (ArC=C) cm⁻¹; (*cis*-**8** diastereoisomer): $\tilde{\nu}$ = 3334 (NH amide), 2956–2815 (CH₂ of piperidine), 2244 (CN), 1642 (C=O amide), 1585 (ArC=C) cm⁻¹. ¹H NMR (CDCl₃) (*trans*-**8** diastereoisomer): δ = 7.23–7.35 (m, 5 H, ArH), 7.03 (s, 2 H, ArH), 6.71–6.75 (d, J = 7.62 Hz, 1 H, NHCO), 4.10–4.12 (m, 1 H, CH piperidine), 3.83–3.88 [s, 9 H, (OCH₃)₃], 3.48–3.63 (dd, J = 3.56 Hz, 2 H, ArCH₂), 3.40–3.41 (br. d, 1 H, CH piperidine), 2.90–3.14 (2 br. d, 1 H, CH piperidine), 1.90–2.33 (m, 4 H, CH₂ piperidine); (*cis*-**8** diastereoisomer): δ = 7.25–7.36 (m, 5 H, ArH), 6.99 (s, 2 H, ArH), 6.39–6.43 (d, J = 8.13 Hz, 1 H, NHCO), 4.17–4.22 (m, 1 H, CH piperidine), 3.86 [s, 9 H, (OCH₃)₃], 3.56 (s, 2 H, ArH), 2.81–3.10 (m, 3 H, CH and CH₂ piperidine), 1.72–2.45 (m, 4 H, CH₂ piperidine) ppm. ¹³C NMR (CDCl₃) (*trans*-**8** diastereoisomer): δ = 167.0 (C=O amide), 153.0, 141.1, 137.5, 128.8 (ArC=C), 128.5, 128.3, 127.2, 104.5 (ArCH=CH), 119.6 (CN), 61.8 (ArCH₂), 60.8, 56.2 (OCH₃), 52.9, 51.9, 28.3 (CH₂ piperidine), 48.0, 34.2 (CH piperidine); (*cis*-**8** diastereoisomer): δ = 166.9 (C=O amide), 153.0, 141.1, 137.5, 128.8 (ArC=C), 128.5, 128.3, 127.2, 104.5 (ArCH=CH), 119.6 (CN), 61.7 (ArCH₂), 60.7, 56.2 (OCH₃), 52.9, 51.9, 28.3 (CH₂ piperidine), 48.0, 34.2 (CH piperidine) ppm.

3-Aminomethyl-1-benzyl-4-(3,4,5-trimethoxybenzoylamino)piperidine (*trans*-13): HCl (12 N, 0.5 mL, 16.16 mmol) and an activated Raney nickel suspension (5 mL) were added to a solution of compound *trans*-8 (4.62 g, 11.29 mmol) in absolute EtOH (80 mL). The resulting mixture was hydrogenated under pressure (40 psi) with shaking at 60 °C for 12 h. The catalyst was removed by filtration and the ethanol was evaporated to dryness. The crude residue was dissolved in dichloromethane and washed with a NaHCO₃ solution and water. The organic layer was then dried with MgSO₄ and concentrated in vacuo. Silica gel column chromatography in CH₂Cl₂ then 97:3 and 93:7 (v/v) CH₂Cl₂/MeOH solutions afforded the pure product *trans*-13 as a white solid (1.68 g, yield 37%). M.p. 70 °C, *R*_f = 0.28 (CH₂Cl₂/MeOH, 80:20, v/v). IR (KBr): $\tilde{\nu}$ = 3368 (NH₂), 3277 (NH amide), 3054 (ArC–H), 2939–2836 (CH₂ of piperidine), 1643 (C=O amide), 1583 (ArC=C), 1126 (OCH₃) cm⁻¹. ¹H NMR (CDCl₃): δ = 7.24–7.35 (m, 5 H, ArH), 7.15 (2 s, 2 H, ArH), 6.97–7.00 (d, *J* = 4.7 Hz, 1 H, NHCO), 4.22–4.24 (m, 1 H, CH piperidine), 3.83–3.93 [s, 9 H, (OCH₃)₃], 3.48–3.63 (m, 4 H, ArCH₂ and NH₂), 3.08–3.25 (2 br. d, 1 H, CH₂ piperidine), 2.64–3.02 (2 br. d, 2 H, CH₂NH₂), 1.98–2.33 (m, 5 H, CH and CH₂ piperidine) ppm. ¹³C NMR (CDCl₃): δ = 167.3 (C=O amide), 153.0, 137.4, 136.8 (ArC=C), 129.3, 129.1, 128.3, 128.2, 127.4, 127.2, 104.8, 104.6 (ArCH=CH), 62.6 (ArCH₂), 60.8, 56.2 (OCH₃), 52.4, 50.2 (CH piperidine), 41.8, 34.1, 31.6 (CH₂ piperidine) ppm.

3-[1-Benzyl-4-(3,4,5-trimethoxybenzoylamino)piperidin-3-ylmethyl]-1-pentylurea (*trans*-14): A solution of pentyl isocyanate (0.42 g, 3.71 mmol) in dry dichloromethane (10 mL) was added dropwise to a solution of *trans*-13 (1.55 g, 3.7 mmol) in dry dichloromethane (60 mL). The reaction mixture was then stirred at room temperature for 2 h and washed successively with water and brine. The organic layer was dried with MgSO₄ and the solvent was evaporated to dryness. The crude product was purified by silica gel column chromatography (CH₂Cl₂/MeOH, 97:3 and 93:7, v/v) to give *trans*-14 as a white solid (1.3 g, yield 65%). M.p. 133 °C, *R*_f = 0.38 (CH₂Cl₂/MeOH, 93:7, v/v). C₂₈H₃₉N₃O₆·½H₂O (522): C 65.01, H 7.84, N 10.46; found C 65.05, H 8.10, N 10.81. IR (KBr): $\tilde{\nu}$ = 3283 (NH amide and ureido), 3053 (ArC–H), 2936 (CH₂ and CH₃ of piperidine and alkyl chain), 1648 (C=O of amide and ureido), 1583 (ArC=C), 1127 (OCH₃) cm⁻¹. ¹H NMR (CDCl₃): δ = 7.90 (br. s, 1 H, NHCO), 7.25–7.45 (m, 7 H, ArH), 5.1–5.4 (br. t, 1 H, CH₂NHCO), 4.60 (br. t, 1 H, CONHCH₂), 4.08–4.29 (m, 1 H, CH piperidine), 3.86–3.93 [s, 9 H, (OCH₃)₃], 3.67–3.80 (m, 1 H, CH₂ piperidine), 3.40–3.57 (dd, *J* = 12.7 Hz, 2 H, ArCH₂), 1.72–3.13 (m, 10 H, CH₂NH, NHCH₂, CH₂ piperidine), 1.36–1.47 [m, 2 H, CH₂(CH₂)₂CH₃], 1.22–1.28 [m, 4 H, (CH₂)₂CH₃], 0.82–0.89 (t, *J* = 6.7 Hz, 3 H, CH₂CH₃) ppm. ¹³C NMR (CDCl₃): δ = 166.5 (C=O amide), 158.0 (C=O ureido), 153.0, 140.5, 129.6 (ArC=C), 128.9, 128.3, 127.3, 104.6 (ArCH=CH), 63.1 (ArCH₂), 60.8, 56.2 (OCH₃), 52.3, 47.1 (CH₂ piperidine), 41.0, 40.7 (CH piperidine), 39.0 (CH₂NHCO), 29.8 (NHCH₂), 28.9 (NHCH₂CH₂), 29.1 (CH₂CH₃), 22.3 (CH₂CH₃), 13.9 (CH₃) ppm.

1-Pentyl-3-[4-(3,4,5-trimethoxybenzoylamino)piperidin-3-ylmethyl]-urea (*trans*-15): Compound *trans*-15 was prepared using a solution of *trans*-14 (1 g, 1.85 mmol) in methanol (60 mL), ammonium formate (1.16 g, 184 mmol) and Pd/C (0.4 g) as the catalyst. The reaction mixture was stirred at reflux for 1 h. After filtration and evaporation of the solvent a white solid was obtained (0.5 g, yield 60%). M.p. 175 °C, *R*_f = 0.27 (CH₂Cl₂/MeOH/NH₄OH, 80:20:2, v/v/v). IR (KBr): $\tilde{\nu}$ = 3311–3306 (NH), 2935–2864 (CH₂ and CH₃), 1634 (C=O), 1581 (ArC=C), 1123 (OCH₃) cm⁻¹. ¹H NMR (CDCl₃): δ = 7.77 (br. s, 1 H, NHCO), 7.26–7.36 (s, 2 H, ArH), 5.81 (br. s, 1 H, CH₂NHCO), 4.56 (br. t, 1 H, CONHCH₂), 4.38–4.5 (m, 1 H, CH piperidine), 3.89–3.99 [2 s, 9 H, (OCH₃)₃], 2.85–3.18 (m, 5 H, CH

piperidine, NHCH₂CH₂), 1.26–1.88 [m, 13 H, HN piperidine, (CH₂)₃, CH and CH₂ piperidine], 0.85–0.91 (t, *J* = 6.7 Hz, 3 H, CH₃) ppm. ¹³C NMR (CDCl₃): δ = 166.7 (C=O amide), 158.8 (C=O ureido), 153.0, 129.6, 104.7 (ArC=C), 60.8, 56.3 (OCH₃), 47.0, 42.0 (CH₂ piperidine), 44.7, 38.9 (CH piperidine), 40.6 (CH₂NHCO), 29.8 (CONHCH₂), 29.5 (CONHCH₂CH₂), 28.9 (NH (CH₂)₂CH₂), 22.3 (CH₂CH₃), 13.9 (CH₃) ppm.

1-Pentyl-3-[1-(3,4,5-trimethoxybenzoyl)-4-(3,4,5-trimethoxybenzoylamino)piperidin-3-ylmethyl]urea (*trans*-16): Compound *trans*-16 was prepared using *trans*-15 (0.47 g, 1.04 mmol), triethylamine (0.41 mL, 2.96 mmol) in dichloromethane (60 mL) and a solution of 3,4,5-trimethoxybenzoyl chloride (0.26 g, 1.13 mmol) in dichloromethane (10 mL). The reaction mixture was stirred at room temperature overnight. Purification by silica gel column chromatography (CH₂Cl₂ and CH₂Cl₂/MeOH, 97:3 and 95:5, v/v) gave the title compound as a white solid (0.43 g, yield 74%). M.p. 179 °C, *R*_f = 0.50 (CH₂Cl₂/MeOH, 93:7, v/v). C₃₂H₄₆N₄O₉·¼H₂O (634.5): C 60.48, H 7.24, N 8.82; found C 60.13, H 7.30, N 8.47. IR (KBr): $\tilde{\nu}$ = 3343–3260 (NH), 2924–2858 (CH₂ and CH₃), 1634 (C=O), 1581 (ArC=C), 1123 (OCH₃) cm⁻¹. ¹H NMR (CDCl₃): δ = 8.17–8.23 (br. s, 1 H, NHCO), 7.29 (s, 2 H, ArH), 6.57 (s, 2 H, ArH), 5.90 (br. s, 1 H, CH₂NHCO), 4.78–5.00 (m, 2 H, CH piperidine and CONHCH₂), 3.80–3.89 [2 s, 18 H, (OCH₃)₆], 2.90–3.78 (m, 4 H, CH₂NHCO and CONHCH₂), 2.15–2.65 (m, 5 H, CH and CH₂ piperidine), 1.23–1.38 [m, 8 H, CH₂ piperidine and -(CH₂)₃CH₃], 0.81–0.87 (t, *J* = 6.4 Hz, 3 H, CH₃) ppm. ¹³C NMR (CDCl₃): δ = 170.9, 166.2 (C=O amide), 159.4 (ureido), 153.4, 153.0, 130.5, 129.4, 104.7, 104.0 (ArC=C), 60.8, 56.2, 56.1 (OCH₃), 47.9 (CH piperidine), 40.4 (CH₂NHCO), 30.0 (CONHCH₂), 29.0 (CONHCH₂CH₂), 22.3 (CH₂CH₃), 13.9 (CH₃) ppm.

1-Benzyl-3-methylamino-4-(3,4,5-trimethoxybenzoylamino)piperidine (*cis*-13): This compound was prepared from *cis*-8 (1.75 g, 4.3 mmol), HCl (12 N, 0.5 mL, 16.16 mmol) and an activated Raney nickel solution (5 mL) using the same procedure as described for *trans*-13. The crude product was purified by silica gel column chromatography (CH₂Cl₂, CH₂Cl₂/MeOH, 97:3 and 93:7, v/v) to give pure *cis*-13 as a white solid (1.45 g, yield 75%). M.p. 115 °C, *R*_f = 0.22 (CH₂Cl₂/MeOH, 80:20, v/v). IR (KBr): $\tilde{\nu}$ = 3313 (NH₂), 3309 (NH amide), 3053 (ArC–H), 2942 (CH₂), 1640 (C=O amide), 1584 (ArC=C) cm⁻¹. ¹H NMR (CDCl₃): δ = 7.58–7.62 (d, *J* = 7.69 Hz, 1 H, NHCO), 7.10–7.27 (m, 7 H, ArH), 4.69 (br. s, 3 H, CH₂NH₂ and CH piperidine), 3.84–3.85 [s, 9 H, (OCH₃)₃], 3.40–3.57 (m, 2 H, ArCH₂), 2.66–3.02 (m, 4 H, CH₂NH₂ and CH₂ piperidine), 1.61–2.07 (m, 5 H, CH and CH₂ piperidine) ppm. ¹³C NMR (CDCl₃): δ = 167.2 (C=O amide), 153.0, 137.4, 136.8 (ArC=C), 129.3, 129.1, 128.3, 128.2, 127.4, 127.2, 104.8, 104.6 (ArCH=CH), 62.6 (ArCH₂), 60.8, 56.4, 56.3 (OCH₃), 52.4, 51.7, 50.2 (CH piperidine), 42.0, 41.8, 34.2, 31.6 (CH₂ piperidine) ppm.

3-[1-Benzyl-4-(3,4,5-trimethoxybenzoylamino)piperidin-3-ylmethyl]-1-pentylurea (*cis*-14): Compound *cis*-14 was prepared from *cis*-13 (0.6 g, 1.47 mmol) and pentyl isocyanate (0.17 g, 1.5 mmol) using the same procedure as for compound *trans*-14 and obtained in the form of a white solid (0.5 g, yield 65%). M.p. 193 °C, *R*_f = 0.29 (CH₂Cl₂/MeOH, 93:7, v/v). C₂₉H₄₂N₄O₅·⅓H₂O (532): C 65.37, H 7.89, N 10.51; found C 65.20, H 8.30, N 10.36. IR (KBr): $\tilde{\nu}$ = 3356–3292 (NH), 2932 (CH₂), 1630 (C=O), 1584 (ArC=C), 1127 (CH₃O) cm⁻¹. ¹H NMR (CDCl₃): δ = 7.24–7.31 (m, 5 H, ArH), 7.14 (s, 2 H, ArH), 6.93–6.97 (d, *J* = 8 Hz, 1 H, NHCO), 5.28–5.30 (br. t, 1 H, CH₂NHCO), 4.30–4.36 (br. t, 1 H, CONHCH₂), 3.88–3.93 [2 s, 9 H, (OCH₃)₃], 3.67–3.76 (m, 1 H, CH piperidine), 3.40–3.62 (dd, *J* = 30.2 Hz, 2 H, ArCH₂), 2.85–3.18 (m, 4 H, CH₂NHCO and CONHCH₂), 2.64–2.74 (m, 1 H, CH piperidine), 1.82–2.17 (m,

6 H, CH and CH₂ piperidine), 1.45–1.63 (m, 2 H, NHCH₂CH₂), 1.26–1.34 [m, 4 H, (CH₂)₂CH₃], 0.87–0.94 (t, *J* = 6.7 Hz, 3 H, CH₃) ppm. ¹³C NMR (CDCl₃): δ = 167.4 (C=O amide), 158.6 (C=O ureido), 153.0, 140.7, 137.5, 129.4, 129.1 (ArC=C), 128.2, 127.2, 104.5 (ArCH=CH), 62.6 (ArCH₂), 60.8, 57.2 (OCH₃), 56.2, 52.0, 40.2 (CH₂ piperidine), 49.7, 43.2 (CH piperidine), 40.5 (CH₂NHCO), 31.7 (CONHCH₂), 29.8 (CONHCH₂CH₂), 29.0 (CONHCH₂CH₂CH₂), 22.3 (CH₂CH₃), 13.9 (CH₃) ppm.

1-Pentyl-3-[4-(3,4,5-trimethoxybenzoylamino)piperidin-3-ylmethyl]urea (*cis*-15): Compound *cis*-15 was prepared from *cis*-14 (0.4 g, 0.76 mmol), ammonium formate (0.8 g, 1.27 mmol) and Pd/C (0.1 g) as the catalyst using the same procedure as for *trans*-15 and gave the title compound in the form of a white solid (0.26 g, yield 79%). M.p. 184 °C, *R*_f = 0.24 (CH₂Cl₂/MeOH/NH₄OH, 80:20:2, v/v/v). IR (KBr): ν̄ = 3317–3286 (NH), 2905 (CH₂), 1629 (C=O), 1583 (ArC=C), 1126 (CH₃O) cm⁻¹. ¹H NMR (CDCl₃): δ = 7.08–7.19 (m, 3 H, ArH and NHCO), 5.52 (br. t, 1 H, CH₂NHCO), 4.50–4.53 (br. t, 1 H, CONHCH₂), 3.88–3.93 [2 s, 9 H, (OCH₃)₃], 3.56–3.66 (m, 1 H, CH piperidine), 2.11–3.24 (m, 9 H, CH₂NHCO, CH₂ and HN piperidine, CONHCH₂), 1.26–1.68 [m, 8 H, CH₂ piperidine, NHCH₂CH₂, (CH₂)₂CH₃], 0.85–0.92 (t, *J* = 6.7 Hz, 3 H, CH₃) ppm. ¹³C NMR (CDCl₃): δ = 166.7 (C=O amide), 158.8 (C=O ureido), 153.0, 129.6, 104.6 (ArC=C), 60.8, 56.2 (OCH₃), 47.0, 42.0 (CH₂ piperidine), 44.6, 38.9 (CH piperidine), 40.5 (CH₂NHCO), 29.8 (CONHCH₂), 29.5 (NHCH₂CH₂), 28.9 (CH₂CH₂CH₃), 22.3 (CH₂CH₃), 13.9 (CH₃) ppm.

1-Pentyl-3-[1-(3,4,5-trimethoxybenzoyl)-4-(3,4,5-trimethoxybenzoylamino)piperidin-3-ylmethyl]urea (*cis*-16): Compound *cis*-16 was prepared from *cis*-15 (0.14 g, 0.32 mmol), triethylamine (0.14 g, 1.38 mmol) and 3,4,5-trimethoxybenzoyl chloride (76 mg, 0.33 mmol) using the same procedure as for *trans*-16 and gave the title compound in the form of a white solid (0.11 g, yield 61%). M.p. 110 °C, *R*_f = 0.37 (CH₂Cl₂/MeOH, 93:7, v/v). C₃₂H₄₆N₄O₉·2/3H₂O (642): C 59.78, H 7.16, N 8.72; found C 59.50, H 7.44, N 9.14. IR (KBr): ν̄ = 3393–3331 (NH), 3053 (ArCH), 2935–2867 (CH₂ and CH₃), 1631 (C=O), 1583 (ArC=C), 1128 (CH₃O) cm⁻¹. ¹H NMR (CDCl₃): δ = 8.92 (br. s, 1 H, NHCO), 7.38 (s, 2 H, ArH), 6.64 (s, 2 H, ArH), 5.63 (br. s, 1 H, CH₂NHCO), 5.3 (br. s, 1 H, CONHCH₂), 4.53 (m, 1 H, CH piperidine), 3.86–3.95 [s, 9 H, (OCH₃)₃], 3.58–3.86 (m, 1 H, CH piperidine), 3.02–3.17 (m, 4 H, CONHCH₂, CH₂NHCO), 1.27–1.99 [m, 12 H, CH₂ piperidine, NHCH₂CH₂, (CH₂)₂CH₃], 0.84–0.91 (t, *J* = 7 Hz, 3 H, CH₃) ppm. ¹³C NMR (CDCl₃): δ = 170.9, 166.2 (C=O amide), 159.4 (C=O ureido), 153.4, 152.9, 130.5, 129.4, 104.7, 104.0 (ArC=C), 60.9, 60.8, 56.2, 56.1 (OCH₃), 47.9 (CH piperidine), 40.4 (CH₂NHCO), 30.0 (CONHCH₂), 29.0 (CONHCH₂CH₂), 22.3 (CH₂CH₃), 13.9 (CH₃) ppm.

Acknowledgments

The authors express their appreciation to Dr. Wafa Sallem for assistance in PAF-induced platelet aggregation measurements.

- [1] J. Benveniste, P. M. Henson, C. G. Cochrane, *J. Exp. Med.* **1972**, *136*, 1356–1377.
- [2] J. Benveniste, *Fed. Proc.* **1974**, *33*, 797.
- [3] J. Benveniste, *Nature* **1974**, *249*, 581–582.
- [4] C. A. Demopoulos, R. N. Pinckard, D. J. Hanahan, *J. Biol. Chem.* **1979**, *254*, 9355–9358.
- [5] M. L. Blank, F. Snyder, L. W. Byers, B. Brooks, E. E. Muirhead, *Biochem. Biophys. Res. Commun.* **1979**, *90*, 1194–1200.
- [6] J. Benveniste, M. Tence, P. Varenne, J. Bidault, C. Boulliet, J. C. R. Polonsky, *Acad. Sci. (Paris)* **1979**, *289*, 1037–1040.

- [7] J. J. Godfroid, F. Heymans, E. Michel, C. Redeuilh, E. Steiner, J. Benveniste, *FEBS Lett.* **1980**, *116*, 161–164.
- [8] F. Heymans, E. Michel, M. C. Borrel, B. Wichrowski, J. J. Godfroid, *C. R. Acad. Sci. (Paris)* **1981**, *293*, 49–52.
- [9] F. Heymans, E. Michel, B. Wichrowski, J. J. Godfroid, O. Convert, E. Coeffier, M. Tencé, J. Benveniste, *Biochem. Biophys. Acta* **1981**, *666*, 230–237.
- [10] M. C. Borrel, C. Broquet, F. Heymans, E. Michel, C. Redeuilh, B. Wichrowski, J. J. Godfroid, *Agents Actions* **1982**, *12*, 709–710.
- [11] F. Kagari, N. Hisao, K. Susumu, I. Keizo, N. Shoshichi, O. Masaji, *Tetrahedron Lett.* **1982**, *23*, 3507–3510.
- [12] B. B. Vargaftig, P. Braquet, *Med. Bull.* **1987**, *43*, 312–335.
- [13] P. Braquet, L. Touqui, T. Y. Shen, B. B. Vargaftig, *Pharmacol. Rev.* **1987**, *39*, 97–145.
- [14] M. C. Venuti, *Annu. Rep. Med. Chem.* **1985**, *20*, 193–202.
- [15] F. Snyder, *Med. Res. Rev.* **1985**, *5*, 107–140.
- [16] F. Snyder, *Annu. Rep. Med. Chem.* **1982**, *17*, 243–252.
- [17] C. M. Winslow and M. L. Lee (Eds.), *New Horizons in Platelet Activating Factor Research*, Wiley, New York, **1987**.
- [18] F. Snyder (Ed.), *Platelet Activating Factor and Related Lipid Mediators*, Plenum Press, New York, **1987**.
- [19] P. Y. Barnes, C. P. Page, P. M. Henson (Eds.), *Platelet Activating Factor and Human Diseases*, Blackwell, Oxford, **1989**.
- [20] D. A. Handley, R. N. Saunders, W. J. Houlihan, J. C. Tomesch (Eds.), *Platelet Activating Factor in Endotoxin and Immune Diseases*, Marcel Dekker, New York, **1990**.
- [21] S. W. Perry, J. A. Hamilton, L. W. Tjoelker, G. Dbaibo, K. A. Dzenko, L. G. Epstein, Y. Hannun, J. S. Whittaker, S. Dewhurst, H. A. Gelbard, *J. Biol. Chem.* **1998**, *273*, 17660–17664.
- [22] D. L. Kolson, E. Lavi, F. Gonzalez-Scarano, *Adv. Virus Res.* **1998**, *50*, 1–47.
- [23] H. A. Gelbard, H. S. Nottet, S. Swindells, M. Jett, K. A. Dzenko, P. Genis, R. White, L. Wang, Y. B. Choi, D. Zhang, S. A. Lipton, W. W. Tourtellote, L. G. Epstein, H. E. Gendelman, *J. Virol.* **1994**, *68*, 4628–4635.
- [24] G. Dive, J. J. Godfroid, J. Lamotte-Brasseur, J. P. Batt, F. Heymans, L. Dupont, P. Braquet, *J. Lip. Mediators* **1989**, *1*, 201–215.
- [25] J. J. Godfroid, G. Dive, J. Lamotte-Brasseur, J. P. Batt, F. Heymans, *Lipids* **1991**, *26*, 1162–1166.
- [26] J. P. Batt, A. Lamouri, F. Tavet, F. Heymans, G. Dive, J. J. Godfroid, *J. Lip. Mediators* **1991**, *4*, 343–346.
- [27] A. Lamouri, F. Heymans, F. Tavet, G. Dive, J. P. Batt, N. Blavet, P. Braquet, J. J. Godfroid, *J. Med. Chem.* **1993**, *36*, 990–1000.
- [28] F. Heymans, G. Dive, A. Lamouri, T. Bellashene, E. Touboul, J. Huet, F. Tavet, C. Redeuilh, J. J. Godfroid, *J. Lip. Mediators Cell Signalling* **1996**, *15*, 161–173.
- [29] N. Serradji, O. Bensaid, M. Martin, E. Kan, N. Dereuddre-Bosquet, C. Redeuilh, J. Huet, F. Heymans, A. Lamouri, P. Clayette, C. Z. Dong, D. Dormont, J. J. Godfroid, *J. Med. Chem.* **2000**, *43*, 2149–2154.
- [30] M. Martin, N. Serradji, N. Dereuddre-Bosquet, G. Le Payec, G. Fichet, A. Lamouri, F. Heymans, J. J. Godfroid, P. Clayette, D. Dormont, *Antimicrob. Agents Chemother.* **2000**, *11*, 3150–3154.
- [31] N. Serradji, M. Martin, O. Bensaid, S. Cisternino, C. Rousselle, N. Dereuddre-Bosquet, J. Huet, C. Redeuilh, A. Lamouri, C. Z. Dong, P. Clayette, J. M. Scherrmann, D. Dormont, F. Heymans, *J. Med. Chem.* **2004**, *47*, 6410–6419.
- [32] a) J. R. Bagley, S. A. Thomas, F. G. Rudo, H. K. Spencer, B. M. Doorley, M. H. Ossipov, T. P. Jerussi, M. J. Benvenga, T. Splauding, *J. Med. Chem.* **1991**, *34*, 827–841; b) V. M. Ivan, D. I. Milovan, M. V. Sonja, P. Milicas, D. M. Ljiljana, D. K. Vesna, *Bioorg. Med. Chem. Lett.* **2000**, *10*, 2011–2014.
- [33] a) J. S. Albert, D. Aharony, D. Andisik, H. Barthlow, P. R. Bernstein, R. A. Bialecki, R. Dedinas, B. T. Dembofsky, D. Hill, K. Kirkland, G. M. Koether, B. J. Kosmider, C. Ohnmacht, W. Palmer, W. Potts, W. Rumsey, L. Shen, A. Shenvi, S.

- Sherwood, P. J. Warwick, K. Russell, *J. Med. Chem.* **2002**, *45*, 3972–3983; b) K. H. Bleicher, Y. Wuthrich, M. De Boni, S. Kolczewski, T. Hoffmann, A. J. Sleight, *Bioorg. Med. Chem. Lett.* **2002**, *12*, 2519–2522.
- [34] K. A. Metwally, D. Malgorzata, T. E. Christina, S. Carol, D. Ann, B. Colleen, K. H. D. Gauthier, T. Milt, A. G. Richard, *J. Med. Chem.* **1998**, *41*, 5084–5093.
- [35] W. Kazmierski, N. Bifulco, H. Yang, L. Boone, F. De Anda, C. Watson, T. Kenakin, *Bioorg. Med. Chem.* **2003**, *11*, 2663–2676.
- [36] M. A. Ashwell, W. R. Solvibile Jr, S. Han, E. Largis, R. Mulvey, J. Tillet, *Bioorg. Med. Chem. Lett.* **2001**, *11*, 3123–3127.
- [37] D. Manetti, E. Martini, C. Ghelardini, S. Dei, N. Galeotti, L. Guandalini, M. Novella Romanelli, S. Scapecchi, E. Teodori, A. Bartolini, F. Gualtieri, *Bioorg. Med. Chem. Lett.* **2003**, *13*, 2303–2306.
- [38] H. Kawamoto, H. Nakashima, T. Kato, S. Arai, K. Kenji, Y. Iwasawa, *Tetrahedron* **2001**, *57*, 981–986.
- [39] S. K. Schlachter, J. T. Poel, C. F. Lawson, D. M. Dinh, M. E. Lajiness, A. G. Romero, A. S. Rees, J. N. Duncan, W. M. Smith, *Eur. J. Pharmacol.* **1997**, *322*, 283–286.
- [40] L. Y. Hu, T. R. Ryder, M. F. Rafferty, C. P. Taylor, M. R. Feng, B. S. Kuo, S. M. Lotarski, G. P. Miljanich, E. Millerman, K. M. Siebers, B. G. Szoke, *Bioorg. Med. Chem.* **2000**, *8*, 1203–1212.
- [41] N. Lalinde, J. Moliterni, D. Wright, H. K. Spencer, M. H. Ossipov, T. C. Spaulding, F. G. Rudo, *J. Med. Chem.* **1990**, *33*, 2876–2882.
- [42] H. Kawamoto, S. Ozaki, Y. Itoh, M. Miyaji, S. Arai, H. Nakashima, T. Kato, H. Ohta, Y. Iwasawa, *J. Med. Chem.* **1999**, *42*, 5061–5063.
- [43] Z. X. Wang, Y. C. Zhu, W. Q. Jin, X. J. Chen, J. Chen, R. Y. Ji, Z. Q. Chi, *J. Med. Chem.* **1995**, *38*, 3652–3659.
- [44] M. Schinnerl, J. K. Murray, J. M. Langenhan, S. H. Gellman, *Eur. J. Org. Chem.* **2003**, *4*, 721–726.
- [45] F. Machetti, F. M. Cordero, F. De Sarlo, A. M. Papini, M. C. Alcaro, A. Brandi, *Eur. J. Org. Chem.* **2004**, *13*, 2928–2935.
- [46] S. Veenstra, K. Hauser, W. Schilling, C. Betschar, W. S. S. Ofner, *Bioorg. Med. Chem. Lett.* **1996**, *6*, 3029–3034.
- [47] P. Jacobsen, I. M. Labouta, K. Schaumburg, E. Falch, P. Krogsgaard-Larsen, *J. Med. Chem.* **1982**, *25*, 1157–1162.
- [48] C. Trapella, R. Guerrini, L. Piccagli, G. Calo, G. Carra, B. Spagnolo, S. Rubini, G. Fanton, C. Hebbes, J. McDonald, D. G. Lambert, D. Regoli, S. Salvadori, *Bioorg. Med. Chem.* **2006**, *14*, 692–704.
- [49] R. F. Borch, M. D. Bernstein, H. D. Durst, *J. Am. Chem. Soc.* **1971**, *93*, 2897–2904.
- [50] D. Russowsky, B. Amaro da Silveira Neto, *Tetrahedron Lett.* **2003**, *44*, 2923–2926.
- [51] T. Nikiforov, S. Stanchez, B. Milenkov, V. Dimitrov, *Heterocycles* **1986**, *24*, 1825–1829.
- [52] R. Fujimoto, Y. Kishi, *Tetrahedron Lett.* **1981**, *22*, 4197–4198.
- [53] G. Bartoli, C. Cimarrelli, E. Marcantoni, G. Palmieri, M. Petrini, *J. Org. Chem.* **1994**, *59*, 5328–5335.
- [54] D. Choi, J. P. Stables, H. Kohn, *J. Med. Chem.* **1996**, *39*, 1907–1916.
- [55] C. J. Marasco Jr, C. Piantadosi, K. L. Meyer, S. Morris-Natschke, K. S. Ishaq, G. W. Small, L. W. Daniel, *J. Med. Chem.* **1990**, *33*, 985–992.
- [56] M. Rowley, D. J. Hallett, S. Goodacre, C. Moyes, J. Crawforth, T. J. Sparey, P. Smita, R. Marwood, P. Shil, T. Steven, L. Hitzel, D. O'Connor, N. Szeto, J. L. Castro, P. H. Hutson, A. M. MacLeod, *J. Med. Chem.* **2001**, *44*, 1603–1614.
- [57] A. Gangjee, J. Shi, S. F. Queener, *J. Med. Chem.* **1997**, *40*, 1930–1936.
- [58] R. Jerzy, M. Pietraseiwick, B. Durszynska, M. T. Cegla, *J. Med. Chem.* **1992**, *35*, 2369–2374.
- [59] A. H. Cook, K. J. Reed, *J. Chem. Soc.* **1945**, 399–401.
- [60] W. D. Kingsbury, J. C. Boehm, D. R. Jakas, K. G. Holden, S. M. Hecht, G. Gallagher, M. J. Caranfa, F. L. McCabe, F. L. Faucette, R. K. Johnson, *J. Med. Chem.* **1991**, *34*, 98–107.
- [61] J. P. Cazenave, J. Benveniste, J. F. Mustard, *Lab. Invest.* **1979**, *41*, 275–285.

Received: July 19, 2007

Published Online: November 12, 2007